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Objective: To determine whether a modified Global Initiative on Obstructive Lung
Diseases (GOLD) classification of chronic obstructive pulmonary disease (COPD)
predicts mortality in a cohort of subjects followed for up to 11 years.
Methods: We analyzed data from 15,759 adult participants, aged 43–66 years at
baseline, in the Atherosclerosis Risk in Communities (ARIC) study. All baseline and
follow-up data were available for 15,440 (97.9%) of the initial participants. We
classified subjects using a modification of the GOLD criteria for COPD (prebronch-
odilator forced expiratory volume in 1 s (FEV1) stratification of disease severity), and
added a
’ ’
restricted’’ category (FEV1/FVC470% and FVCo80% predicted). We used
Cox proportional hazard models to determine the risk of impaired lung function on
subsequent mortality, after adjusting for age, race, sex and smoking status.
Results: 1242 (8.0%) subjects died by the end of 1997. The overall rate of death was
8.9 per 1000 person years, but varied from 5.4/1000 among normal subjects to 42.9/
1000 among subjects with GOLD Stage 3 or 4 COPD. After adjusting for covariates, all
GOLD categories, along with the restricted category, predicted a higher risk of
death: GOLD Stage 3 or 4, hazard ratio (HR) 5.7, 95% confidence interval (CI) 4.4,
7.3; GOLD Stage 2 HR 2.4, 95% CI 2.0, 2.9; GOLD Stage 1 HR 1.4, 95% CI 1.1, 1.6;
GOLD Stage 0 HR 1.5, 95% CI 1.3, 1.8; and restricted HR 2.3, 95% CI 1.9, 2.8.Elsevier Ltd. All rights reserved.
ulmonary and Critical Care Medicine, University of Kentucky Medicial Center, 800 Rose Street,
l.: +1 859 323 5045; fax: +1 859 257 2418.
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D.M. Mannino et al.116Conclusion: The modified GOLD classification system of COPD predicts mortality in
this cohort of middle-aged Americans followed for up to 11 years.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is an
important cause of morbidity and mortality in the
US.1 Restrictive lung disease, which may have
several different etiologies, is also an important
cause of disability, morbidity and mortality in the
US.2,3 Although tobacco smoking is the most
important risk factor for both the development
and progression of COPD, it is not the only one, with
asthma,4 exposure to ambient pollutants in the
home and workplace,5 and respiratory infections6,7
also being important.
A large proportion of the morbidity and mortality
that occurs in people with lung disease is not
pulmonary8,9 which raises the possibility that the
presence of lung disease may be an indicator of
either susceptibility to the development of other
diseases or may be associated with systemic inflam-
mation, which may then lead to these other
diseases.10–13 Impaired lung function has been pre-
viously shown to predict mortality,14–20 but none of
these studies used the recently developed interna-
tional Global Initiative on Obstructive Lung Disease
(GOLD) guidelines for the staging of COPD severity.21
The GOLD guidelines, however, do not define restric-
tive disease.
We used a modification of the GOLD classification
criteria, incorporating a classification for restric-
tive disease, to examine the relation between
impaired lung function and mortality in a large
cohort of US adults aged 43–66 at baseline and
followed for up to 11 years.Methods
Study population
The Atherosclerosis Risk in Communities (ARIC)
study was initiated in 1986 as a longitudinal,
population-based study of the etiology and clinical
sequelae of atherosclerosis. The ARIC cohort
includes 15,759 subjects aged 43–66 years at
baseline from four US communities: Forsyth County,
NC; Jackson, MS; suburbs of Minneapolis, MN; and
Washington County, MD. ARIC participants were
selected from the entire population by probability
sampling in the communities other than Jackson,
where probability sampling was used to selectAfrican Americans only. ARIC participants under-
went pulmonary function testing during a baseline
clinical examination and provided information on
history of respiratory symptoms and diagnoses, BMI,
smoking history, and medical history. Study proto-
cols were approved for protection of human
subjects. Details of the ARIC study are published
elsewhere.22
Subjects
Our analysis was limited to ARIC participants who
provided baseline information on respiratory symp-
toms and diagnoses, who underwent pulmonary
function testing at the baseline examination,
and for whom follow-up data were available
(n ¼ 15; 440).
Pulmonary function data
Spirometry was conducted using a volume displace-
ment, water-sealed spirometer. At least three
acceptable spirograms were obtained from a mini-
mum of five forced expirations. The best single
spirogram was identified by computer and confirmed
by a technician. Quality assurance was provided by
the ARIC Pulmonary Function Center, and the
procedures followed contemporary American Thor-
acic Society guidelines.23 Several measures of lung
function were used: the forced expiratory volume in
1 s (FEV1), the forced vital capacity (FVC), and the
FEV1/FVC ratio. Linear regression models were
used to create prediction equations for FEV1 and
FVC based on age, sex, race, and height among
asymptomatic never-smokers who did not have a
diagnosis of any lung disease (asthma, chronic
bronchitis, or emphysema). These prediction equa-
tions (based on race, gender, age, and height) follow
standard methods24 for creating spirometric refer-
ence values as follows: For African-American males:
FEV1¼1.473+0.089height0.028age (n ¼ 311),
FVC¼3.703+0.131 height0.024 age (n ¼ 311);
for African-American females: FEV1¼1.029+0.072
height0.024age (n ¼ 1076), FVC¼2.333+0.104
height0.027 age (n ¼ 1077); for White males:
FEV1¼2.599+0.116 height0.031 age (n ¼ 913),
FVC ¼ 5.179+0.169 height0.030 age (n ¼ 913);
for White females: FEV1 ¼ 0.6861+0.0755 height
0.028age (n ¼ 2257), FVC¼2.377+0.114 height
0.027 age (n ¼ 2257).
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Using a modification of the criteria developed by
the GOLD,21 we classified subjects according to
their GOLD stages of COPD: GOLD stage 3 or 4
(FEV1/FVCo0.70 and FEV1o50% predicted), GOLD
stage 2 (FEV1/FVCo0.70 and FEV1X50 to o80%
predicted), GOLD Stage 1 (FEV1/FVCo0.70 and
FEV1X80%), restricted (FEV1/FVCX0.70 and
FVCo80% predicted), GOLD stage 0 (presence of
respiratory symptoms in the absence of any lung
function abnormality), and no lung disease. Bronch-
odilator response was not evaluated in this survey
so classification is based on the
’ ’
prebronchodila-
tor’’ level.
Respondents with positive responses to
’ ’
Have you
ever smoked cigarettes?’’ and
’ ’
Do you now smoke
cigarettes?’’ were classified as
’ ’
ever smokers’’ and
’ ’
current smokers,’’ respectively. Pipe or cigar
smokers were also considered as
’ ’
smokers’’. Pack-
years of cigarettes smoked were calculated for
current and former smokers. BMI was calculated as
weight divided by height squared (kg/m2).25 Educa-
tion level was categorized as less than high school,
completion of high school, or more than high school.
We defined a subject as having a respiratory
symptom if he responded positively to any of the
following questions: Do you usually have a cough?;
Do you usually bring up phlegm from your chest?;
Does your chest ever sound wheezy or whistling
apart from colds?; Do you have to walk slower than
people of your age on the level because of
breathlessness?; Are you too breathless to leave
the house or breathless on dressing or undressing?
Deaths
Cause of death was obtained from death certifi-
cates. We used the International Classification of
Disease, Ninth Revision (ICD-9) codes to classify
death as respiratory (ICD-9 490–496), lung cancer
(ICD-9 162), cardiovascular (ICD-9 410–429), or
other (all others).
Analysis
All analyses were conducted with SAS version 8.2
(SAS Institute, Cary, NC), SUDAAN version 8.0 (RTI,
Research Triangle Park, NC) and SPSS version 10
(SPSS Inc, Chicago, IL, USA). Our primary outcome
of interest was death, and the main predictor of
interest in our analysis was lung function and the
presence of respiratory symptoms at the baseline
examination. Cox proportional hazard regression
models were developed using the SUDAAN proce-dure SURVIVAL to account for differential follow-up
in cohort participants. Time of follow-up was used
as the underlying time metric. For deaths, the exit
date was the date of death reported on the death
certificate and, for survivors, the exit date was the
date the participant was last known to be alive.
Plots of the log–log survival curves for each
covariate were used to show that the proportional
hazards assumptions were met. Age, sex, race,
smoking status, education level, body mass index,
pack-years of cigarette smoking, and years since
last smoked were included in the adjusted models
and the models were evaluated for interactions. We
also used alternative classifications of lung function
(including our
’ ’
restricted’’ group in either the
Normal or GOLD 0 groups) to examine how the
’ ’
restricted’’ category influenced the results.Results
The entire ARIC cohort consisted of 15,792 sub-
jects. We excluded 287 subjects who were of race
other than white or black and an additional 65
subjects who were missing data on one of the other
variables in our analysis, leaving 15,440 subjects in
our analytic cohort. Excluded subjects did not vary
significantly with regard to age, sex, or smoking
status from included subjects (P40:05 for all
comparisons).
The demographic characteristics of the studied
population are displayed in Table 1. Overall, 271
(1.8%) of participants had GOLD stage 3 or 4 COPD
and 1484 (9.6%) had GOLD stage 2 at baseline. One
thousand two hundred and forty-two subjects died
during the follow-up period, which was a mean of
9.0 years and a maximum of 11.1 years for the
population. Subjects with lung function impairment
or respiratory symptoms had a higher mortality
during follow-up than normal subjects (Table 1,
Fig. 1). Cause of death by GOLD category at
baseline is displayed in Table 2.
A higher proportion of subjects with lung func-
tion impairment reported at least one respiratory
symptom compared to normal subjects, and there
was evidence that people with lower lung function
report more symptoms (Table 3).
After adjusting for covariates, all GOLD cate-
gories, along with the restricted category, pre-
dicted a higher risk of death: GOLD 3 or 4, hazard
ratio (HR) 5.7, 95% confidence interval (CI) 4.4, 7.3;
GOLD 2 HR 2.4, 95% CI 2.0, 2.9; GOLD 1 HR 1.4, 95%
CI 1.1, 1.6; GOLD 0 HR 1.5, 95% CI 1.3, 1.8; and
restricted HR 2.3, 95% CI 1.9, 2.8. GOLD staging of
lung function and the presence of respiratory
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Table 1 Demographic distribution and outcomes of study participant.
N Deaths (%) Person years Death rate/1000 person years
Age group
43–49 4120 139 (3.4) 37,775 3.7
50–54 4012 223 (5.6) 36,694 6.1
55–59 3772 350 (9.3) 33,888 10.3
60–66 3536 530 (15.0 ) 30,823 17.2
Sex
Male 6925 709 (10.2) 61,816 11.5
Female 8515 533 (6.3) 77,364 6.9
Race
White 11311 756 (6.7) 102,984 7.3
Black 4129 486 (11.8) 36,197 13.4
Smoking status
Current smoker 4409 552 (12.5) 38,770 14.2
Former smoker 4972 380 (7.6) 45,003 8.4
Never smoker 6059 310 (5.1) 55,407 5.6
Pack years
60+ 756 162 (21.4) 6359 25.5
40–59 1342 200 (14.9) 11,707 17.1
20–39 2982 296 (9.9) 26,606 11.1
1–19 3593 211 (17.0) 32,777 6.4
Unknown 257 28 (10.9) 2253 12.4
0 6510 345 (5.3) 59,478 5.8
Body mass index
o20 139 27 (19.4) 1176 23.0
20–24 4970 377 (7.6) 44,836 8.4
25–29 6067 457 (7.5) 54,931 8.3
X30 4264 381 (8.9) 38,238 10.0
Education level
o12 3671 518 (14.1) 32,195 16.1
12 4996 336 (6.7) 45,249 7.4
X12 6773 388 (5.7) 61,737 6.3
GOLD category
GOLD 3 or 4 271 92 (34.0) 2143 42.9
GOLD 2 1484 232 (15.6) 12,852 18.1
GOLD 1 1679 137 (8.1) 15,031 9.1
GOLD 0 2244 204 (9.1) 20,191 10.1
Restricted 1101 150 (13.6) 9644 15.6
Normal 8661 427 (4.9) 79,317 5.4
Total 15440 1242 (8.0) 139,180 8.9
From the Atherosclerosis Risk in Communities (ARIC) study 1986–1989 and follow-up through 1997.
GOLD stage 3 or 4 (FEV1/FVCo0.70 and FEV1o50% predicted), GOLD stage 2 (FEV1/FVCo0.70 and FEV1X50 to o80%
predicted), GOLD Stage 1 (FEV1/FVCo0.70 and FEV1X80%), restricted (FEV1/FVCX0.70 and FVCo80% predicted), GOLD stage 0
(presence of respiratory symptoms in the absence of any lung function abnormality), and no lung disease.
D.M. Mannino et al.118symptoms were related to an increased risk of
mortality both before and after adjustment for the
covariates of age, sex, race, smoking status, pack-
years of cigarettes, body mass index, and educa-
tional level (Table 4). At each GOLD stage, subjects
reporting at least one respiratory symptom had ahigher risk of death than those without symptoms
(Fig. 2 for GOLD stage 3 or 4, other figures available
from author). Including the
’ ’
Restricted’’ subjects
in either the GOLD 0 or normal categories did not
significantly change the results (data not shown but
available from the author).
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Table 3 Proportion of subjects reporting at least
one chronic respiratory symptom.
N Percentage
reporting
respiratory
GOLD classification of lung disease and mortality 119Discussion
In this analysis of a large cohort of middle-aged
adults in the US, we have demonstrated the GOLD
stages of COPD are associated with higher mortality
in up to 11 years of follow-up. Additionally, we have
demonstrated that the presence of respiratory
symptoms predicts higher mortality at every level
of lung function impairment, including subjects
with
’ ’
normal’’ lung function. These findings are
similar to those we reported previously in a US
population followed for up to 22 years.9 In that
study, the adjusted HR for subjects with GOLD
stage 3 or 4 COPD was 2.7 (95% CI 2.1, 3.5). In that
study, though, the age range of the baseline
population was much wider (25–75 years old vs.
43–66 years old) and the proportion of currentTable 2 Underlying cause of death among 1242 deceden
Deaths Underlying caus
Respiratory
GOLD 3 or 4y 92 31.5
GOLD 2 232 3.5
GOLD 1 137 0.7
Restricted 150 1.3
GOLD 0 204 0.5
Normal 427 0.5
Total 1242 3.5
From the Atherosclerosis Risk in Communities (ARIC) study 1986–
Based on International Classification of Disease, Ninth Revision
lung cancer (ICD-9 162), cardiovascular (ICD-9 410-429), or other
yGOLD stage 3 or 4 (FEV1/FVCo0.70 and FEV1o50% predicte
predicted), GOLD Stage 1 (FEV1/FVCo0.70 and FEV1X80%), restric
(presence of respiratory symptoms in the absence of any lung fun
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Figure 1 Kaplan–Meier survival curves for subjects
included in the study, stratified by lung function level
at baseline. From the Atherosclerosis Risk in Communities
(ARIC) study 1986–1989 and follow-up through 1997.smokers was much higher (42% vs. 28%) than the
current study.
Several other studies have demonstrated that
lower levels of lung function lead to higher
mortality.15,16,18,20,26 This higher mortality is re-
lated to pulmonary related mortality, lung cancer,
and cardiovascular disease.9,27,28 Factors such as
chronic muscle wasting, autonomic dysfunction,
systemic inflammation, or oxidative stress may be
responsible for this increased risk.29–34ts in the study.
e of death (%)
Lung cancer Cardiac Other
23.9 13.0 31.5
25.4 27.6 43.5
18.3 24.8 56.2
7.3 39.3 52.0
8.3 35.3 55.9
6.3 30.2 63.0
13.0 29.8 53.8
1989 and follow-up through 1997.
(ICD-9) codes to classify death as respiratory (ICD-9 490-496),
(all others).
d), GOLD stage 2 (FEV1/FVCo0.70 and FEV1X50 to o80%
ted (FEV1/FVCX0.70 and FVCo80% predicted), GOLD stage 0
ction abnormality), and no lung disease.
symptoms
GOLD 3 or 4 271 81.9
GOLD 2 1484 52.0
GOLD 1 1679 29.6
Restricted 1101 35.4
Normal/GOLD 0y 10,905 20.5
Total 15,440 26.7
From the Atherosclerosis Risk in Communities (ARIC) study
1986–1989 and follow-up through 1997.
GOLD stage 3 or 4 (FEV1/FVCo0.70 and FEV1o50%
predicted), GOLD stage 2 (FEV1/FVCo0.70 and FEV1X50
to o80% predicted), GOLD Stage 1 (FEV1/FVCo0.70 and
FEV1X80%), restricted (FEV1/FVCX0.70 and FVCo80%
predicted), GOLD stage 0 (presence of respiratory
symptoms in the absence of any lung function abnorm-
ality), and no lung disease.
yNormal and GOLD 0 are included in the same row to
show the prevalence of respiratory symptoms in subjects
with neither obstructed nor restricted lung function.
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Table 4 Results of Cox proportional Hazard Models predicting survival.
Symptoms N Unadjusted hazard ratio
(95% confidence interval)
Adjusted hazard ratio (95%
confidence interval)
GOLD 3 or 4 Yes 222 9.2 (7.3, 11.7) 4.5 (3.5, 5.8)
No 49 4.0 (2.1, 7.7) 1.9 (0.97, 3.6)
GOLD 2 Yes 772 3.9 (3.2, 4.7) 2.1 (1.7, 2.6)
No 712 2.9 (2.3, 3.6) 1.6 (1.3, 2.1)
GOLD 1 Yes 497 2.5 (1.9, 3.3) 1.6 (1.2, 2.1)
No 1182 1.4 (1.1, 1.7) 1.0 (0.8, 1.3)
Restricted Yes 390 4.1 (3.2, 5.2) 2.8 (2.2, 3.7)
No 711 2.3 (1.8, 2.9) 1.8 (1.4, 2.3)
GOLD 0 Yes 2244 1.9 (1.6, 2.2) 1.6 (1.3, 1.9)
Normal No 8661 Referent Referent
Results are both unadjusted and adjusted for age, sex, smoking status, body mass index, race, pack-years of smoking, race, and
educational level. From the Atherosclerosis Risk in Communities (ARIC) study 1986–1989 and follow-up through 1997.
GOLD stage 3 or 4 (FEV1/FVCo0.70 and FEV1o50% predicted), GOLD stage 2 (FEV1/FVCo0.70 and FEV1X50 to o80%
predicted), GOLD Stage 1 (FEV1/FVCo0.70 and FEV1X80%), restricted (FEV1/FVCX0.70 and FVCo80% predicted), GOLD stage 0
(presence of respiratory symptoms in the absence of any lung function abnormality), and no lung disease.
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Figure 2 Kaplan–Meier survival curves for subjects
included in the study with GOLD Stage 3 or 4 chronic
obstructive pulmonary disease (FEV1/FVCo0.70 and
FEV1o50% predicted), stratified by respiratory symptoms
at baseline. From the Atherosclerosis Risk in Communities
(ARIC) study 1986–1989 and follow-up through 1997.
D.M. Mannino et al.120In this analysis we separated out individuals with
’ ’
restricted’’ spirometry, as we have done in
previous analyses.9,28 These subjects are not
currently addressed in the GOLD criteria,35
yet they may comprise an important pheno-
type of COPD or represent patients with
comorbid disease that contributes to morbidity
and mortality.
Respiratory symptoms, particularly chronic mu-
cous hypersecretion and dyspnea, have been shown
to be related to higher mortality in COPD pa-
tients.36,37 New in our study is the finding that
GOLD stage 0 COPD, which is respiratory symptoms
in the absence of lung function impairment, had an
increased risk of mortality. One study has shownthat GOLD stage 0 COPD (defined only by the
symptom of coughing up phlegm 3 months a year)
did not predict progression of disease, but mortal-
ity was not evaluated in that study.38 Our study
differed from that one in that we looked at all
respiratory symptoms and had mortality as an
endpoint.
This analysis has certain limitations. Smoking
status, which is an important predictor of mortal-
ity, was not independently validated with biomar-
kers. Respiratory symptoms were all self-reported
and not independently validated. The strict
classification using GOLD criteria requires the use
of a post-bronchodilator FEV1, which was not
available in this study.21 We did not have data on
total lung capacity, which is needed for the strict
definition of restrictive lung disease,39 available, so
it is possible that some people we classified as
restrictive may have had other pathology or normal
lung volumes.40
In conclusion, we found that in this large
prospectively followed cohort of middle-aged
adults in the US both lung function impairment,
determined using a modification of the GOLD
criteria for COPD, and respiratory symptoms result
in increased risk of mortality in up to 11 years of
follow-up. These findings provide a further stimulus
for finding out why lung function impairment is such
a powerful predictor of mortality, and further
emphasizes the potential value of spirometry in
assessing overall health status. The finding also
emphasizes the predictive value of respiratory
symptoms and reminds us that symptoms have
important predictive value in assessing health
status.
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